1FASSETT R G, DRIVER R, HEALY H, et al. Comparison of markers of oxidative stress, inflammation and arterial stiffness between incident hemodialysis and peritoneal dialysis patientsan observational study[ J]. BMC Nepbrol, 2009,10:8.
2DIAZ-BUXO J A, GOTLOIB L. Agents that modulate peritoneal membrane structure and function [J]. Perit Dial Int, 2007,27(1) :16-30.
3FASSETY R G, DRIVER R, HEALY H, et al. Cardiovascular disease in peritoneal dialysis patients [J]. Panminerva Med,2009,51 (3) :151-161.
4ZHENG Z, YE R, YU X, et al. Peritoneal dialysis solutions disturb the balance of apoptosis and proliferation of peritoneal cells in chronic dialysis model [ J]. Adv Petit Dial, 2001,17: 53-57.
5SCHWEDLER S, SCHINZEL R, VAITH P, et al. Inflammation and advanced glycation end products in uremia:simple coexistence, potentiation or causal relationship? [ J]. Kidney Int Suppl, 2001,78 :S32-36.
6XUZG, KIM K S, PARK H C, et al. High glucose activates the p38 MAPK pathway in cultured human peritoneal mesothelial cells [ J ]. Kidney Int, 2003,63 (3) :958- 968.
7GOTLOIB L. Mechanisms of cell death during peritoneal dialysis. A role for osmotic and oxidative stress [J]. Contrib Nephrol, 2009,163:35-44.
8GUNAL A I, CELIKER H, of oxidative stress inhibition USTUNDAG B, et al. The effect with trimetazidine on the peritonealalterations induced by hypertonic peritoneal dialysis solution[ J]. J Nephrol,2003,16(2) :225-230.
9NOH H, KIM J S, HANK H, et al. Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane [ J ]. Kidney Int, 2006,69 ( 11 ) : 2022-2028.
10BOZKURT D, HUR E, ULKUDEN B, et al. Can N-acetylcysteinepreserve peritoneal function and morphology in en- capsulating peritoneal sclerosis? [J]. Perit Dial Int, 2009, 29 Suppl 2 : S202-205.
